LinQNotes: Get the “why” behind treatment decisions
Structured healthcare data tells you what happened. LinQNotes reveals why—empowering you to lead with confidence, clarity, and speed. This infographic shows how LinQNotes, powered by NorstellaLinQ EMR data, delivers: Clinical rationale behind switching or stopping therapy Insights into access challenges and prior authorization delays Social determinants of health (SDOH) and patient context Download the full […]
NorstellaLinQ: Gain Real-Time Insights on High-Risk Patient Populations with Real-World Data
In this use case, find out how MMIT, using NorstellaLinQ, used real-world data to help a manufacturer specializing in multiple myeloma therapies get a clearer picture of high-risk patients and the physicians treating them.
NorstellaLinQ: A powerful force for bringing real-world data together
NorstellaLinQ consolidates multiple real-world data sources—including labs, claims, and EMR—into a single, powerful linked dataset to better support clients and patients. By integrating structured and unstructured data, Norstella uses advanced technology to extract detailed insights on biomarkers and other entities, extending and deepening understanding of the patient journey, prognosis, and optimal intervention timing. This linked […]
NorstellaLinQ: Creating real-world data products for what’s next
This abstract explores how a client-focused approach aims to bring organizations closer to patients by deeply understanding the context surrounding targeted patient populations, including social determinants of health, prior therapies, and ongoing clinical trials. Rather than relying on high-level descriptions, the emphasis is on interpreting what these contextual factors mean in practice, identifying barriers that […]
NorstellaLinQ: Better together: Getting the full patient picture
NorstellaLinQ is a unified platform that integrates clinically rich, domain-specific data with real-world data and proprietary assets from across all Norstella brands to create robust clinical context and a comprehensive view of the market. By enabling seamless blending of data from different businesses, it supports the development of innovative data products and novel perspectives that […]
NorstellaLinQ: From pipeline to patient with comprehensive data
NorstellaLinQ unites several previously strong organizations and their robust product portfolios to create what is described as the industry’s most complete and comprehensive data asset spanning from pipeline to patients. This integrated asset enables holistic, end-to-end visibility across therapy areas, including market access, coverage, and real-world data on patients receiving a therapy, as well as […]
NorstellaLinQ: Illuminating the rare disease journey
In rare disease, traditional real-world data sources often fall short, leaving teams across research, medical, and commercial functions with blind spots. But with NorstellaLinQ, biopharma’s first fully integrated data asset, rare disease doesn’t mean unreachable. This infographic explores how NorstellaLinQ lets you: Capture every patient and complete every journey Reveal hidden patients earlier Track real-world […]
NorstellaLinQ unstructured data: Stop searching. Start knowing.
Learn how NorstellaLinQ’s unstructured data can help you narrow down from millions of patients to the few who matter most—with the only solution that connects diagnosis to clinical reality. What’s inside: Using the example of breast cancer, we show how NorstellaLinQ starts wide to identify a broad population using ICD-10 codes. Then we narrow down […]
NorstellaLinQ: Empowering Early Disease Diagnosis with Real-World Data
In this use case, find out how MMIT, using NorstellaLinQ, merged unstructured EMR data with structured data to help a global pharma company detect disease screening patterns and drive commercialization strategies.
NorstellaLinQ: Refining Rare Disease Targeting with Real-World Data
In this use case, learn how MMIT, using NorstellaLinQ, identified a narrower patient population and improved the client’s physician targeting.